AU2013336807B2 - Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine - Google Patents

Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine Download PDF

Info

Publication number
AU2013336807B2
AU2013336807B2 AU2013336807A AU2013336807A AU2013336807B2 AU 2013336807 B2 AU2013336807 B2 AU 2013336807B2 AU 2013336807 A AU2013336807 A AU 2013336807A AU 2013336807 A AU2013336807 A AU 2013336807A AU 2013336807 B2 AU2013336807 B2 AU 2013336807B2
Authority
AU
Australia
Prior art keywords
trifluoromethyl
pyridin
acetamide
compound
solvents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013336807A
Other languages
English (en)
Other versions
AU2013336807A1 (en
Inventor
Murat Acemoglu
Nicole Bieri
Jorg Brozio
Dietmar Flubacher
Pascal Michel
Rasmus Mose
Frank Schaefer
Hans Stettler
Maria Caterina Testa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013336807A1 publication Critical patent/AU2013336807A1/en
Priority to AU2016238941A priority Critical patent/AU2016238941A1/en
Application granted granted Critical
Publication of AU2013336807B2 publication Critical patent/AU2013336807B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2013336807A 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine Active AU2013336807B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016238941A AU2016238941A1 (en) 2012-10-23 2016-10-07 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717237P 2012-10-23 2012-10-23
US61/717,237 2012-10-23
US201361842101P 2013-07-02 2013-07-02
US61/842,101 2013-07-02
PCT/EP2013/071996 WO2014064058A1 (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016238941A Division AU2016238941A1 (en) 2012-10-23 2016-10-07 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Publications (2)

Publication Number Publication Date
AU2013336807A1 AU2013336807A1 (en) 2015-03-05
AU2013336807B2 true AU2013336807B2 (en) 2016-10-27

Family

ID=49448162

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013336807A Active AU2013336807B2 (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
AU2016238941A Abandoned AU2016238941A1 (en) 2012-10-23 2016-10-07 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016238941A Abandoned AU2016238941A1 (en) 2012-10-23 2016-10-07 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Country Status (15)

Country Link
US (1) US9637468B2 (enExample)
EP (1) EP2912030B1 (enExample)
JP (1) JP6267213B2 (enExample)
KR (1) KR102128127B1 (enExample)
CN (1) CN104736532B (enExample)
AU (2) AU2013336807B2 (enExample)
BR (1) BR112015007243B1 (enExample)
CA (1) CA2885471C (enExample)
ES (1) ES2605638T3 (enExample)
IN (1) IN2015DN01331A (enExample)
MX (1) MX360703B (enExample)
PL (1) PL2912030T3 (enExample)
PT (1) PT2912030T (enExample)
RU (1) RU2646760C2 (enExample)
WO (1) WO2014064058A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24269B1 (es) 2011-09-27 2017-08-08 Novartis Ag 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN105050602B (zh) * 2013-01-12 2018-05-25 张大为 作为pi3激酶抑制剂的吡啶化合物
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US10100031B2 (en) 2014-04-22 2018-10-16 Universitaet Basel Manufacturing process for triazine, pyrimidine and pyridine derivatives
WO2016050201A1 (zh) * 2014-09-29 2016-04-07 山东轩竹医药科技有限公司 高选择性取代嘧啶类pi3k抑制剂
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
CN106543140A (zh) * 2015-09-21 2017-03-29 苏州晶云药物科技有限公司 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
CN107793394A (zh) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 一种生产选择性pi3k抑制剂的系列关键中间体
WO2020127208A2 (en) * 2018-12-18 2020-06-25 Astrazeneca Ab Pharmaceutical process and intermediates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044727A2 (en) * 2010-10-01 2012-04-05 Novartis Ag Manufacturing process for pyrimidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4061194B2 (ja) * 2001-02-08 2008-03-12 富山化学工業株式会社 ６−置換アルキルアミノ−３−ピリジルホウ酸誘導体またはその塩およびそれらの製造法
ES2412273T3 (es) * 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044727A2 (en) * 2010-10-01 2012-04-05 Novartis Ag Manufacturing process for pyrimidine derivatives

Also Published As

Publication number Publication date
ES2605638T3 (es) 2017-03-15
KR20150072408A (ko) 2015-06-29
EP2912030A1 (en) 2015-09-02
PT2912030T (pt) 2016-11-30
BR112015007243B1 (pt) 2022-02-08
JP2016502510A (ja) 2016-01-28
EP2912030B1 (en) 2016-08-31
KR102128127B1 (ko) 2020-06-30
RU2646760C2 (ru) 2018-03-07
CN104736532B (zh) 2017-04-05
WO2014064058A1 (en) 2014-05-01
CA2885471C (en) 2021-02-23
MX360703B (es) 2018-11-14
CN104736532A (zh) 2015-06-24
IN2015DN01331A (enExample) 2015-07-03
AU2016238941A1 (en) 2016-11-03
US20150246897A1 (en) 2015-09-03
BR112015007243A2 (pt) 2017-07-04
PL2912030T3 (pl) 2017-02-28
MX2015005188A (es) 2015-09-07
JP6267213B2 (ja) 2018-01-24
AU2013336807A1 (en) 2015-03-05
RU2015119259A (ru) 2016-12-20
CA2885471A1 (en) 2014-05-01
US9637468B2 (en) 2017-05-02

Similar Documents

Publication Publication Date Title
AU2013336807B2 (en) Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
WO2009083739A1 (en) Method of synthesis of bosentan, its polymorphic forms and its salts
IL281292B2 (en) Processes for the preparation of a diarylthiohydantoin compound
AU2016387566A1 (en) An improved process for the preparation of Regorafenib
WO2014020467A2 (en) Process for the preparation of pyrazole substituted aminoheteroaryl compounds
JP4152353B2 (ja) 殺菌性ピリジン化合物
US7714127B2 (en) Process for making heteroaryl amine intermediate compounds
CA3029361A1 (en) New processes for the preparation of vemurafenib
TW200922923A (en) Process for producing toluidine compound
TWI685485B (zh) 阿卡替尼（acalabrutinib）之製造方法
JP2011526257A (ja) Ｎ−フェニル−ｎ−（４−ピペリジニル）アミド塩の製造方法
WO2015163446A1 (ja) イミダゾール化合物の製造方法
CN1325490C (zh) 制备高纯度羟基吲哚基乙醛酰胺的方法
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
CN108473510B (zh) 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
JP5080050B2 (ja) 光学活性なピペラジン化合物の製造方法
JP2021075535A (ja) ピリミジン誘導体およびそれらの中間体を調製する化学的方法
WO2023187833A1 (en) A novel salt of bempedoic acid
JP2019196359A (ja) ピリミジン誘導体およびそれらの中間体を調製する化学的方法
KR20230027177A (ko) 1,4-이치환 피리다진 화합물의 제조 공정
WO2007086559A1 (ja) テトラヒドロピラン化合物の製造方法
JP2018131415A (ja) Ｌ−カルノシン誘導体またはその塩の製造方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)